GSK Stock Surges 39.39% in Volume, Ranks 339th as Blenrep Approval Boosts Market Confidence

On April 21, 2025, GSK's trading volume reached 2.40 billion, marking a 39.39% increase from the previous day, ranking 339th in the day's stock market. GSK's stock price rose by 1.45%, marking two consecutive days of gains, with a total increase of 3.05% over the past two days.

GSK's Blenrep, an antibody-drug conjugate, has been authorized by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for treating multiple myeloma. This approval includes two combination therapies: with bortezomib plus dexamethasone for patients who have received at least one prior therapy, and with pomalidomide plus dexamethasone for those who have received a prior therapy including lenalidomide.

This authorization is supported by robust Phase III data from the DREAMM-7 and DREAMM-8 trials, which demonstrated superior efficacy results. The approval is expected to extend survival and remission for patients with multiple myeloma, a cancer marked by remission and relapse.

GSK's belantamab mafodotin therapy has cleared several regulatory hurdles in Europe over the past two years. The European Medicines Agency (EMA) accepted GSK’s marketing authorization application in July 2024, and the therapy is currently under review in several other countries, including Japan, China, Canada, and Switzerland.